Cantor Fitzgerald Predicts Stronger Earnings for Humacyte

Humacyte, Inc. (NASDAQ:HUMA) – Stock analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for Humacyte in a research note issued to investors on Wednesday, April 23rd. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($0.71) for the year, up from their prior estimate of ($0.95). The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.07. The company had revenue of $7.23 million during the quarter, compared to the consensus estimate of $0.64 million.

Several other research firms also recently weighed in on HUMA. Benchmark reiterated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Wednesday, March 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Humacyte presently has a consensus rating of “Buy” and an average target price of $13.71.

Humacyte Trading Down 2.7 %

Humacyte stock opened at $1.44 on Friday. The business’s 50 day simple moving average is $2.36 and its 200 day simple moving average is $3.91. Humacyte has a 12 month low of $1.15 and a 12 month high of $9.97. The company has a market cap of $223.37 million, a price-to-earnings ratio of -1.07 and a beta of 1.62.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of HUMA. Barclays PLC lifted its stake in Humacyte by 177.6% in the third quarter. Barclays PLC now owns 236,742 shares of the company’s stock worth $1,288,000 after purchasing an additional 151,458 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Humacyte by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock worth $11,101,000 after purchasing an additional 179,120 shares during the period. Brookstone Capital Management purchased a new stake in Humacyte in the fourth quarter worth about $56,000. Clarus Wealth Advisors bought a new stake in shares of Humacyte during the fourth quarter valued at approximately $207,000. Finally, ARS Investment Partners LLC lifted its position in Humacyte by 17.8% during the fourth quarter. ARS Investment Partners LLC now owns 99,419 shares of the company’s stock valued at $502,000 after buying an additional 15,000 shares during the period. 44.71% of the stock is currently owned by institutional investors.

Insider Transactions at Humacyte

In other news, Director Kathleen Sebelius bought 50,000 shares of Humacyte stock in a transaction that occurred on Tuesday, April 8th. The shares were acquired at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the purchase, the director now directly owns 91,207 shares in the company, valued at $120,393.24. The trade was a 121.34 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Dale A. Sander acquired 20,000 shares of the business’s stock in a transaction dated Thursday, April 10th. The stock was purchased at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. This represents a 97.09 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 83,993 shares of company stock valued at $118,224. 11.20% of the stock is currently owned by company insiders.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.